NEW YORK, Feb. 21, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc. (“Regulus”) (NASDAQ:RGLS) between February 17, 2016 and January 27, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Jin v. Regulus Therapeutics Inc., et al. (Case No. 17cv0267 LAB JMA) in the USDC for the Southern District of California. To get more information go to:
http://www.zlk.com/pslra/regulus-therapeutics
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, Regulus made materially false and/or misleading statements and/or failed to disclose that: (i) RG-101 was not safe and well tolerated by all patients in the ongoing studies, (ii) cases of serious adverse events (“SAE”) were discovered, (iii) the SAEs were proof of serious concerns about the safety profile of RG-101, (iv) Regulus would likely need to produce extensive data to the U.S. Food and Drug Administration (“FDA”) to continue clinical trials of RG-101, and (v) as a result of the foregoing, Defendants’ statements about Regulus’ business and prospects were false and misleading and/or lacked a reasonable basis.
Take Action: if you suffered a loss in Regulus you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


OpenAI Addresses Security Vulnerability in macOS App Certification Process
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



